Between May 1977 and April 1980, 238 patients with operable breast cancer were treated with adjuvant fluorouracil, doxorubicin, and cyclophosphamide (FAC) chemotherapy. All patients were randomized to receive FAC alone or FAC with nonspecific immunotherapy with Bacillus Calmette-Guerin (BCG) vaccine. A randomization for routine postoperative irradiation was included in the study in May 1978. At the median follow-up of 33 months, 53 patients had developed recurrent disease. U p to the present time, there have been no significant differences in the disease-free survival of patients treated with FAC alone from those treated with FAC + BCG (P = 0.21). The disease-free survival for patients treated with and without routine postoperative irradiation was similar (P = 0.99). Disease-free survival of premenopausal and postmenopausal women was similar. The overall estimate of disease-free survival was 72% at 3 years. Cancer 53384-389, 1984. T HAS BEEN ESTABLISHED that combination chemo-I therapy is superior to single agents in the treatment of patients with early and advanced breast cancer.'.' Several combinations of cyclophosphamide, methotrexate, fluorouracil, vinblastine, doxorubicin, and prednisone have been evaluated in the treatment of advanced breast cancer. It has been shown that doxorubicin-containing combinations result in higher remission rates for patients than do non-doxorubicin-containing At our institute, a combination of fluorouracil, doxorubicin, and cyclophosphamide (FAC) has been utilized in the treat-From the Departments of Medicine (Medical Breast).